Product

Company

Clareo Health | Investigation of the Cylex® ImmuKnow® Assay

NCT00569842·1 site·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Indiana University

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Patients who are undergoing allogeneic HSCT using a myeloablative preparative regimen for any of the following disorders are eligible:
1. Acute leukemia
2. Non-Hodgkin's Lymphoma
3. Chronic lymphocytic leukemia
4. Hodgkin's disease
5. Multiple myeloma
6. Myelodysplastic Syndromes
7. Myeloproliferative Disorders
8. Aplastic Anemia
9. Chronic myelogenous leukemia

The record

StatusCompleted

PhaseNo phase

Taking part45

StartedNov 2007

UpdatedSep 11, 2014

Conditions

Where1